trial · primary record
Durvalumab
Metastatic Angiosarcoma
| Phase | Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 75 |
| Primary completion | 2027-06-30 |
| Primary endpoint | Response rate (Cohorts 1 and 2) |
| Registry ID | NCT04668300 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:55:05.123Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04668300
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Durvalumab · approval
- Durvalumab · compound